913358-93-7

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-((R)-6,7-Dimethoxy-1-(4-(trifluoromethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide is used as a pharmaceutical agent for the treatment of various disorders. Its unique structure and functional groups allow it to interact with specific biological targets, modulating their activity and providing therapeutic benefits.
Used in Drug Development:
In the field of drug development, (R)-2-((R)-6,7-Dimethoxy-1-(4-(trifluoromethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide serves as a potential lead molecule for the discovery of new drugs. Its specific interactions with biological targets can be further optimized to improve its efficacy, selectivity, and safety profile, leading to the development of novel therapeutic agents.
Used in Research Applications:
(R)-2-((R)-6,7-Dimethoxy-1-(4-(trifluoromethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide is also used in research settings to study the mechanisms of action and potential applications of similar compounds. Its unique properties and interactions with biological systems can provide valuable insights into the development of new therapeutic strategies and drug candidates.
Used in Insomnia Treatment:
As an orally active orexin antagonist (OX1 and OX2 dual receptor antagonist), (R)-2-((R)-6,7-Dimethoxy-1-(4-(trifluoromethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide is used in the treatment of insomnia. It works by blocking the orexin receptors, which play a crucial role in regulating wakefulness, thus promoting sleep and improving sleep quality.

Upstream product

• 871224-64-5 almorexant 
• 871224-68-9 (S)-2-(methylamino)-2-oxo-1-phenylethyl 4-methylbenzenesulfonate 
• 1169801-28-8 (S)-6,7-dimethoxy-1-(4-(trifluoromethyl)phenethyl)-1,2,3,4-tetrahydroisoquinoline acetate 
• 1296659-30-7 (1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-1,2,3,4-tetrahydro-isoquinoline hydrochloride 

Relevant academic research and scientific papers

CRYSTALLINE AND AMORPHOUS FORMS OF ALMOREXANT AND A METHOD OF THEIR PREPARATION

The invention relates to crystalline and amorphous forms of (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl] -3,4-dihydro- 1H-isoquinolin-2-yl} -N-methyl-2-phenyl- acetamide hydrochloride (I) (almorexant) and a method of their preparation

PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY PURE TRISUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVE

The present invention relates to a process for the preparation of the compound of formula 7, which process comprises: the asymmetric transfer hydrogenation of the compound of formula 4 * HX: wherein HX is as decribed in the description; in the presence of

TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE

The present invention relates to the compound of formula 7*acetate (see below), a process for its preparation, and its use

PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE

The present invention relates to a process for the preparation of the compound of formula (7) which process comprises the hydrogenation of the compound of formula (4) using bis[chloro-1,5-cyclooctadiene-iridium], (S)-i-dicyclohexylphosphino-2-[(S)-α-(dime

PROCESS FOR THE PREPARATION OF AN ENANTIOMERIC TRISUBSTITUTED 3,4-DIHYDRO-ISOQUINOLINE DERIVATIVE

The present invention relates to a process for the preparation of the compound of formula (7) which process comprises the hydrogenation of the compound of formula (4) using bis[chloro-1,5-cyclooctadiene-iridium], (S)-i -dicyclohexylphosphino- 2-[(S)-α-(di

TRISUBSTITUTED 3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUND, PROCESS FOR ITS PREPARATION, AND ITS USE

The present invention relates to the compound of formula (7*)acetate (see below), a process for its preparation, and its use.